Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
During the last 10 years, a lot of progress has been made in unraveling the pathogenic cascade leading to Alzheimer disease (AD). According to the most widely accepted hypothesis, production and aggregation of the amyloid β (Aβ) peptide plays a key role in AD, and thus therapeutic interference with these processes is the subject of intense research. However, some important aspects of the disease mechanism are not yet fully understood. There is no consensus as yet on whether the disease acts through a loss- (LOF) or a gain-of-function (GOF) mechanism. While for many years, an increased production of Aβ42 was considered to be the prime culprit for the initiation of the disease process, and accordingly Aβ42 is elevated by AD-related presenilin(PS) mutations, recent data strongly suggest that PS mutations also lead to a LOF of PS towards a plethora of its substrates including amyloid precursor protein. How this PS LOF, especially decreased Aβ40 secretion due to mutant PS, impacts on the disease pathogenesis is yet to be elucidated. Secondly, vascular abnormalities – frequently observed to co-occur with AD – might also play a critical role in the initiation and aggravation of AD pathology given that the elimination of Aβ through a vascular route is an important brain Aβ clearance mechanism and its failure leads to formation of vascular amyloidosis and dense-core plaques. In this review, we will first focus on the important issue of a LOF versus a GOF mechanism for AD due to mutant PS, as well as on the possible role of vascular damage and reduced perfusion in AD. Special emphasis will be given to some of the AD mouse models that have helped to gain insights into the disease mechanism. Secondly, considering these mechanistic insights, we will discuss some therapeutic strategies which are currently in clinical or preclinical trials for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“The first successful mouse models were APP transgenic models that progressively developed extracellular plaques, for instance, PDAPP and Tg2576 mice expressing the APP/Indiana (V717F) and APP/Swedish (APPK670M/N671L) mutations, respectively [”
BackgroundMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“and Aβ42 is the first and predominant species accumulating in plaques in the AD brain [”
BackgroundCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Self-citationBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“caution is needed because the reduction of the amount of Aβ40 might mimic the effect of PS mutations and in this way worsen instead of ameliorate the phenotype. In this eventuality, strategies aimed at altering APP processing to cause a selective increase in Aβ40 could be useful.Some nonsteroidal anti-inflammatory dru…”
BackgroundHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 1×
“where both pathological and genetic analyses are eagerly awaited. These results all suggest that partial loss of many functional proteins can eventually lead to neurodegeneration.To conclude, it is becoming obvious that Aβ-independent pathway(s) are also an important mechanism of neurodegeneration. This is especially…”
BackgroundBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Dorpe, J. V., Hellings, P., Gorselink, M., Heymans, S., et al. (2001) · Nature Genetics · doi:10.1038/88842 · Cited by 1,007
Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965
Skeletal and CNS Defects in Presenilin-1-Deficient Mice
Shen, J., Bronson, R. T., Chen, D. F., Xia, W., Selkoe, D. J., & Tonegawa, S. (1997) · Cell · doi:10.1016/s0092-8674(00)80244-5 · Cited by 959
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Saura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 1×
“Aβ-Independent Neurodegeneration Altered Cellular Signaling in Dementia A number of studies suggest that neurodegeneration caused by PS FAD mutations can occur via an Aβ-independent mechanism with the involvement of a PS LOF. The proof of principle that (partial) PS LOF can induce neurodegenerative processes came from…”
ResultRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“These changes likely resulted from the inhibition of notch cleavage. In order to solve this issue, it will be very important to understand the mechanism of the independent regulation of γ- and e-cleavage, which will be helpful in the design of γ-site-specific inhibitors that do not alter e-site cleavage. Using such co…”
BackgroundAβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 1×
“A possible protective role of Aβ40 is also derived from recent studies utilizing a fourth transgenic mouse model, the BRI-Aβ40 and BRI-Aβ42 transgenic mice that selectively produce Aβ40 or Aβ42, respectively, without utilizing human APP [”
BackgroundAβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 1×
“The Tg2576 and PSAPP mouse models as well as the Flemish AD brain show the formation of large dense cores associated with vessels, while diffuse plaques are less abundant, as well as a preponderance of Aβ40. The crucial role of Aβ40 in vascular amyloidosis was also demonstrated by a study of mice overexpressing the AP…”
BackgroundSong, W., Nadeau, P., Yuan, M., Yang, X., Shen, J., & Yankner, B. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6959 · Cited by 362 · cited 1×
“This LOF activates GSK-3 and thus leads to tau overphosphorylation.PS1 is involved in the processing of multiple proteins besides APP, and in mammalian cells PS1 FAD mutations were shown to inhibit γ-secretase-mediated cleavage of several substrates. For instance, PS FAD mutations cause a loss of γ-secretase-mediated…”
BackgroundTarkowski, E., Issa, R., Sjögren, M., Wallin, A., Blennow, K., Tarkowski, A., & Kumar, P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00285-8 · Cited by 360 · cited 1×
“It was observed in this study that VEGF acts most efficiently in close proximity to its injection site, suggesting that in order to have a beneficial effect on the cerebral vascular system, this compound should preferably be injected directly into the brain.The level of VEGF is upregulated in AD patients, specifically…”
BackgroundIntraneuronal Aβ accumulation and origin of plaques in Alzheimer's disease
Gouras, G. K., Almeida, C. G., & Takahashi, R. H. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.022 · Cited by 338 · cited 1×
“In support of these in vitro data, in vivo evidence for the role of reduced Aβ40 levels in AD pathogenesis has come from recent studies utilizing transgenic and knockin mouse models. The first study models the APP-Au mutation (APPT714I) that has a drastic reduction of Aβ40. We showed that APP-Au mice deposit Aβ inside…”
ResultDe Jonghe, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1665 · Cited by 223
Kumar-Singh, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2589 · Cited by 158
Self-citationCarlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
Dense-Core Senile Plaques in the Flemish Variant of Alzheimer's Disease Are Vasocentric
Kumar-Singh, S., Cras, P., Wang, R., Kros, J. M., van Swieten, J., Lübke, U., Ceuterick, C., Serneels, S., Vennekens, K., Timmermans, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64207-1 · Cited by 114 · cited 1×
“This is definitely supporting a GOF of the mutant A β ; however, most of these mutations also have additional phenotypes like vascular amyloidosis which also plays a role in neurodegeneration, and this is different from classical AD pathology where only wild-type Aβ deposits in predominantly Aβ plaques [”
BackgroundSelf-citation
Cited by
Reassessing the amyloid cascade hypothesis of Alzheimer's disease
Pimplikar, S. W. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.015 · Cited by 375
Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1
Lim, J., Crespo-Barreto, J., Jafar-Nejad, P., Bowman, A. B., Richman, R., Hill, D. E., Orr, H. T., & Zoghbi, H. Y. (2008) · Nature · doi:10.1038/nature06731 · Cited by 311
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Drachman, D. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.11.003 · Cited by 224
“It is now clear that most PS mutations produce a loss of function, with decreased amounts of total Ab production [42,43].”
BackgroundCrespo-Barreto, J., Fryer, J. D., Shaw, C. A., Orr, H. T., & Zoghbi, H. Y. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001021 · Cited by 136
“In Alzheimer disease (AD), increased aggregation of the amyloid beta peptides induced by AD-related presenilin mutations is thought to be a consequence of a dominant gain-of-function mechanism [49].”
Background
Metadata
- Authors
- Van Broeck, B., Van Broeckhoven, C., & Kumar-Singh, S.
- Venue
- Neurodegenerative Diseases
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 4
- Issue
- 5
- Pages
- 349-365
- ISSN
- 1660-2854 (ISSN-L)
- 1660-2862
- OpenAlex
- W2062977922
- Cited by
- 65
- References
- 29
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.